The aim of this study was to evaluate the risk factors for recurrence of borderline ovarian tumours. This study investigated 127 women who were finally diagnosed with borderline epithelial ovarian tumours. Most of them were diagnosed in stage I (83.4%). With a median follow-up of 81.8 months (range: 14-205), the median time to recurrence was 22.4 months (range: 3-74). Five-year recurrence-free survival (RFS) and overall survival (OS) rates were 85.8% and 97.6%, respectively. In multivariate analysis, invasive implants and fertility-sparing surgery were found to be independent prognostic factors for 5-year RFS. Overall, 20 patients (15.7%) experienced relapse within the observation period. Although there is no consensus about high-risk category of borderline ovarian tumours, invasive implants and conservative surgery were closely related to the recurrence. Patients presenting these risk factors should undergo closer follow-up.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/01443615.2016.1188276 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk factors for postoperative hypoalbuminemia in ovarian cancer: a predictive nomogram.
BMC Womens Health
March 2025
Department of Anesthesiology, Ya'an People's Hospital, Ya'an, Sichuan, China.
Objective: Postoperative hypoalbuminemia increases the risk of delayed wound healing and infections and prolongs hospital stays, and may even increases mortality. Hypoalbuminemia is commonly observed after radical ovarian cancer surgery. The primary aim of this study is to determine risk factors for postoperative hypoalbuminemia after radical ovarian cancer surgery, and to develop a prediction nomogram for its prevention and management.
View Article and Find Full Text PDFUsability, Acceptability, and Barriers to Implementation of a Collaborative Agenda-Setting Intervention (CASI) to Promote Person-Centered Ovarian Cancer Care: Development Study.
JMIR Cancer
March 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, BP1143, Boston, MA, 02215, United States, 1 8572150743, 1 6175828550.
Background: People with advanced ovarian cancer and their caregivers report unmet supportive care needs. We developed a Collaborative Agenda-Setting Intervention (CASI) to elicit patients' and caregivers' needs through the patient portal before a clinic visit and to communicate these needs to clinicians using the electronic health record.
Objective: We aimed to assess the usability and acceptability of the CASI and identify barriers to and facilitators of its implementation.
Introduction of AGPAT3 gene as a regulator of cisplatin resistance in A2780 ovarian endometrioid carcinoma cell line.
PLoS One
March 2025
Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Ovarian cancer therapy remains a challenge for human health, partly due to chemotherapy resistance. Understanding the molecular mechanisms underlying this resistance is crucial. Therefore, to identify genes involved in cisplatin resistance in ovarian cancer, RNA-seq analysis of A2780cp (cisplatin-resistant) and A2780 (cisplatin-sensitive) cell lines was performed, revealing 1-acylglycerol-3-phosphate O-acyltransferase 3 (AGPAT3) as a differentially expressed candidate gene.
View Article and Find Full Text PDFA Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy.
J Vis Exp
February 2025
ProMab Biotechnologies;
Chimeric antigen receptor (CAR) T cell therapy has emerged as a pioneering cancer treatment, achieving unprecedented success in treating certain hematological malignancies such as lymphomas and leukemias. However, as more cancer patients receive CAR-T cell therapies, treatment-associated secondary primary malignancies are increasingly being reported partly due to unexpected CAR transgene insertion, raising serious safety concerns. To address this issue, we describe here a nonviral, non-integrating approach to generate transient CAR-T cells using mRNA.
View Article and Find Full Text PDFLearning directed acyclic graphs for ligands and receptors based on spatially resolved transcriptomic data of ovarian cancer.
Brief Bioinform
March 2025
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1399 Park Ave, New York, NY 10029, United States.
To unravel the mechanism of immune activation and suppression within tumors, a critical step is to identify transcriptional signals governing cell-cell communication between tumor and immune/stromal cells in the tumor microenvironment. Central to this communication are interactions between secreted ligands and cell-surface receptors, creating a highly connected signaling network among cells. Recent advancements in in situ-omics profiling, particularly spatial transcriptomic (ST) technology, provide unique opportunities to directly characterize ligand-receptor signaling networks that power cell-cell communication.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!